{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T03:56:26Z","timestamp":1793073386004,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:00Z","timestamp":1653004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:00Z","timestamp":1653004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Westmead Charitable Trust"},{"name":"Westmead Medical Research Foundation"},{"DOI":"10.13039\/501100001775","name":"University of Technology Sydney","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001775","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cervical dystonia (CD) is an isolated, focal, idiopathic dystonia affecting the neck and upper back. CD is usually treated by botulinum neurotoxin (BoNT) injections into the dystonic muscles; however, about 20% of people will discontinue BoNT therapy. This systematic review aimed to determine the barriers to satisfaction and facilitators that could improve satisfaction with BoNT therapy for people with CD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A database search for journal articles investigating satisfaction with BoNT treatment in CD identified seven qualitative studies and one randomised controlled trial. Results were grouped into \u201cdirect\u201d and \u201cindirect\u201d barriers and facilitators.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The most reported direct barrier to satisfaction with BoNT was treatment non-response, reported by up to 66% of participants. Other direct barriers included negative side effects, early wearing-off of treatment effect and inexperience of the treating physician. Indirect barriers included limited accessibility to treatment (including cost) and personal choice. Direct facilitators of satisfaction with BoNT included relief of symptoms and flexible re-treatment intervals. Indirect facilitators included easy accessibility to treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Despite BoNT having a discontinuation rate of only 20%, it appears a much greater proportion of people with CD are dissatisfied with this treatment. As BoNT is currently the main treatment offered to people with CD, efforts to improve treatment response rates, reduce side effects and make treatment more flexible and readily available should be adopted to improve the quality of life for people with CD.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10072-022-06114-8","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T04:03:14Z","timestamp":1653019394000},"page":"4663-4670","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The barriers and facilitators to satisfaction with botulinum neurotoxin treatment in people with cervical dystonia: a systematic review"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7172-3992","authenticated-orcid":false,"given":"Melani J.","family":"Boyce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alana B.","family":"McCambridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynley V.","family":"Bradnam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen G.","family":"Canning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianne P.","family":"Verhagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,20]]},"reference":[{"issue":"7","key":"6114_CR1","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/mds.25475","volume":"28","author":"A Albanese","year":"2013","unstructured":"Albanese A, Bhatia K, Bressman SB, DeLong MR, Fahn S, Fung VSC, Teller JK (2013) Phenomenology and classification of dystonia: a consensus update. Mov Disord 28(7):863\u2013873. https:\/\/doi.org\/10.1002\/mds.25475","journal-title":"Mov Disord"},{"key":"6114_CR2","first-page":"332","volume-title":"Movement Disorders 2","author":"S Fahn","year":"1987","unstructured":"Fahn S, Marsden CD, Calne DB (1987) Classification and investigation of dystonia. In: Marsden CD (ed) Mov Disord 2. Butterworth, London, pp 332\u2013352"},{"issue":"4","key":"6114_CR3","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s00415-014-7586-2","volume":"262","author":"C Comella","year":"2015","unstructured":"Comella C, Bhatia K (2015) An international survey of patients with cervical dystonia. J Neurol 262(4):837\u2013848. https:\/\/doi.org\/10.1007\/s00415-014-7586-2","journal-title":"J Neurol"},{"key":"6114_CR4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.parkreldis.2017.11.004","volume":"47","author":"B Demartini","year":"2018","unstructured":"Demartini B, Scattolini C, D\u2019Agostino A, Elia AE, Romito LM, Gambini O (2018) Prevalence of psychiatric disorders in patients with inherited or idiopathic dystonia. Parkinsonism Relat Disord 47:84\u201385. https:\/\/doi.org\/10.1016\/j.parkreldis.2017.11.004","journal-title":"Parkinsonism Relat Disord"},{"key":"6114_CR5","doi-asserted-by":"publisher","unstructured":"Jahanshahi M, Marsden CD (1990) A longitudinal follow-up study of depression, disability, and body concept in torticollis. Behav Neurol 3(4).:https:\/\/doi.org\/10.3233\/ben-1990-3403","DOI":"10.3233\/ben-1990-3403"},{"key":"6114_CR6","doi-asserted-by":"publisher","unstructured":"Castel\u00e3o M, Marques RE, Duarte GS, Rodrigues FB, Ferreira J, Sampaio C, Costa J (2017) Botulinum toxin type A therapy for cervical dystonia. Cochrane Database of Syst Rev (12). https:\/\/doi.org\/10.1002\/14651858.CD003633.pub3","DOI":"10.1002\/14651858.CD003633.pub3"},{"issue":"35","key":"6114_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3389\/fneur.2017.00035","volume":"8","author":"MF Contarino","year":"2017","unstructured":"Contarino MF, Van Den Dool J, Balash Y, Bhatia K, Giladi N, Koelman JH, Tijssen MA (2017) Clinical Practice: Evidence-Based Recommendations for the Treatment of Cervical Dystonia with Botulinum Toxin. Front Neurol 8(35):35. https:\/\/doi.org\/10.3389\/fneur.2017.00035","journal-title":"Front Neurol"},{"issue":"Suppl 1","key":"6114_CR8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1468-1331.2006.01440.x","volume":"13","author":"CL Comella","year":"2006","unstructured":"Comella CL, Thompson PD (2006) Treatment of cervical dystonia with botulinum toxins. Eur J Neurol 13(Suppl 1):16\u201320. https:\/\/doi.org\/10.1111\/j.1468-1331.2006.01440.x","journal-title":"Eur J Neurol"},{"key":"6114_CR9","doi-asserted-by":"publisher","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, The PG (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. PLoS Med 6(7):e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097","DOI":"10.1371\/journal.pmed.1000097"},{"issue":"3","key":"6114_CR10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/XEB.0000000000000062","volume":"13","author":"C Lockwood","year":"2015","unstructured":"Lockwood C, Munn Z, Porritt K (2015) Qualitative research synthesis: methodological guidance for systematic reviewers utilizing meta-aggregation. Int J Evid Based Healthc 13(3):179\u2013187","journal-title":"Int J Evid Based Healthc"},{"issue":"1","key":"6114_CR11","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/1531-8257(200001)15:1<150::AID-MDS1024>3.0.CO;2-X","volume":"15","author":"A Brashear","year":"2000","unstructured":"Brashear A, Bergan K, Wojcieszek J, Siemers ER, Ambrosius W (2000) Patients\u2019 perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type A. Mov Disord 15(1):150\u2013153","journal-title":"Mov Disord"},{"issue":"4","key":"6114_CR12","doi-asserted-by":"publisher","first-page":"776","DOI":"10.3390\/toxins5040776","volume":"5","author":"CE Gill","year":"2013","unstructured":"Gill CE, Manus ND, Pelster MW, Cook JA, Title W, Molinari AL, Charles D (2013) Continuation of long-term care for cervical dystonia at an academic movement disorders clinic. Toxins 5(4):776\u2013783. https:\/\/doi.org\/10.3390\/toxins5040776","journal-title":"Toxins"},{"issue":"3","key":"6114_CR13","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/mds.10659","volume":"19","author":"P Haussermann","year":"2004","unstructured":"Haussermann P, Marczoch S, Klinger C, Landgrebe M, Conrad B, Ceballos-Baumann A (2004) Long-term follow-up of cervical dystonia patients treated with botulinum toxin A. Mov Disord 19(3):303\u2013308","journal-title":"Mov Disord"},{"issue":"6","key":"6114_CR14","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1002\/mds.10252","volume":"17","author":"GY Hsiung","year":"2002","unstructured":"Hsiung GY, Das SK, Ranawaya R, Lafontaine AL, Suchowersky O (2002) Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord 17(6):1288\u20131293","journal-title":"Mov Disord"},{"issue":"6","key":"6114_CR15","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1007\/s00415-016-8136-x","volume":"263","author":"HA Jinnah","year":"2016","unstructured":"Jinnah HA, Goodmann E, Rosen AR, Evatt M, Freeman A, Factor S (2016) Botulinum toxin treatment failures in cervical dystonia: causes, management, and outcomes. J Neurol 263(6):1188\u20131194","journal-title":"J Neurol"},{"key":"6114_CR16","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.2147\/PPA.S106560","volume":"10","author":"M Poliziani","year":"2016","unstructured":"Poliziani M, Koch M, Liu X (2016) Striving for more good days: patient perspectives on botulinum toxin for the treatment of cervical dystonia. Patient Prefer Adherence 10:1601\u20131608","journal-title":"Patient Prefer Adherence"},{"issue":"4","key":"6114_CR17","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1053\/apmr.2001.21843","volume":"82","author":"J Whitaker","year":"2001","unstructured":"Whitaker J, Butler A, Semlyen JK, Barnes MP (2001) Botulinum toxin for people with dystonia treated by an outreach nurse practitioner: a comparative study between a home and a clinic treatment service. Arch Phys Med Rehabil 82(4):480\u2013484","journal-title":"Arch Phys Med Rehabil"},{"issue":"10","key":"6114_CR18","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1007\/s10072-017-3078-3","volume":"38","author":"P Latino","year":"2017","unstructured":"Latino P, Castelli L, Prosperini L, Marchetti MR, Pozzilli C, Giovannelli M (2017) Determinants of botulinum toxin discontinuation in multiple sclerosis: a retrospective study. Neurol Sci 38(10):1841\u20131848. https:\/\/doi.org\/10.1007\/s10072-017-3078-3","journal-title":"Neurol Sci"},{"issue":"4","key":"6114_CR19","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/j.1440-1630.2012.01027.x","volume":"59","author":"G Williams","year":"2012","unstructured":"Williams G, Olver J, de Graaff S, Singer BJ (2012) The use of botulinum toxin type A in the management of adult-onset focal spasticity: A survey of Australian allied health professionals. Aust Occup Ther J 59(4):257\u2013264. https:\/\/doi.org\/10.1111\/j.1440-1630.2012.01027.x","journal-title":"Aust Occup Ther J"},{"issue":"23","key":"6114_CR20","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1056\/NEJMsb1503104","volume":"372","author":"JL Jameson","year":"2015","unstructured":"Jameson JL, Longo DL (2015) Precision medicine \u2014 personalized, problematic, and promising. N Engl J Medicine 372(23):2229\u20132234. https:\/\/doi.org\/10.1056\/NEJMsb1503104","journal-title":"N Engl J Medicine"},{"issue":"8","key":"6114_CR21","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41582-020-0370-2","volume":"16","author":"CG Canning","year":"2020","unstructured":"Canning CG, Allen NE, Nackaerts E, Paul SS, Nieuwboer A, Gilat M (2020) Virtual reality in research and rehabilitation of gait and balance in Parkinson disease. Nat Rev Neurol 16(8):409\u2013425. https:\/\/doi.org\/10.1038\/s41582-020-0370-2","journal-title":"Nat Rev Neurol"},{"key":"6114_CR22","doi-asserted-by":"publisher","unstructured":"Liebeskind DS (2021) Precision medicine for intracranial atherosclerotic disease. Front Neurol 12(132). https:\/\/doi.org\/10.3389\/fneur.2021.646734","DOI":"10.3389\/fneur.2021.646734"},{"issue":"7","key":"6114_CR23","doi-asserted-by":"publisher","first-page":"650","DOI":"10.3390\/jpm11070650","volume":"11","author":"T Mishima","year":"2021","unstructured":"Mishima T, Fujioka S, Morishita T, Inoue T, Tsuboi Y (2021) Personalized medicine in Parkinson\u2019s disease: new options for advanced treatments. J Personalized Med 11(7):650. https:\/\/doi.org\/10.3390\/jpm11070650","journal-title":"J Personalized Med"},{"key":"6114_CR24","doi-asserted-by":"crossref","unstructured":"Rodrigues FB, Duarte GS, Marques RE, Castelao M, Ferreira J, Sampaio C, Costa J (2020) Botulinum toxin type A therapy for cervical dystonia. Cochrane Database of Syst Rev 2020(11):no pagination(CD003633)","DOI":"10.1002\/14651858.CD003633.pub4"},{"issue":"12","key":"6114_CR25","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s00702-013-1048-3","volume":"120","author":"VG Evidente","year":"2013","unstructured":"Evidente VG, Fernandez HH, LeDoux MS, Brashear A, Grafe S, Hanschmann A, Comella CL (2013) A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin((R))) in cervical dystonia. J Neural Transm (Vienna) 120(12):1699\u20131707. https:\/\/doi.org\/10.1007\/s00702-013-1048-3","journal-title":"J Neural Transm (Vienna)"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-06114-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-022-06114-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-06114-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T13:17:49Z","timestamp":1659532669000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-022-06114-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,20]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["6114"],"URL":"https:\/\/doi.org\/10.1007\/s10072-022-06114-8","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,20]]},"assertion":[{"value":"17 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This systematic review did not require ethical approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}